Join Growin Stock Community!

Atossa therapeutics, inc.ATOS.US Overview

US StockHealthcare
(No presentation for ATOS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ATOS AI Insights

ATOS Overall Performance

ATOS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ATOS Recent Performance

-

Atossa therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ATOS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ATOS Key Information

ATOS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ATOS Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Price of ATOS

ATOS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ATOS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.77
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.77
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ATOS's latest earnings report released?

    The most recent financial report for Atossa therapeutics, inc. (ATOS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATOS's short-term business performance and financial health. For the latest updates on ATOS's earnings releases, visit this page regularly.

  • How much cash does ATOS have?

    At the end of the period, Atossa therapeutics, inc. (ATOS) held Total Cash and Cash Equivalents of 51.96M, accounting for 0.9 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ATOS's EPS continuing to grow?

    According to the past four quarterly reports, Atossa therapeutics, inc. (ATOS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ATOS?

    Atossa therapeutics, inc. (ATOS)'s Free Cash Flow (FCF) for the period is -6.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 26.3% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.